Form 8-K - Current report:
SEC Accession No. 0000950170-25-003280
Filing Date
2025-01-08
Accepted
2025-01-08 07:05:08
Documents
13
Period of Report
2025-01-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20250108.htm   iXBRL 8-K 45632
2 EX-99.1 eypt-ex99_1.htm EX-99.1 24952
3 GRAPHIC img96707757_0.jpg GRAPHIC 99780
  Complete submission text file 0000950170-25-003280.txt   321079

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20250108.xsd EX-101.SCH 23898
15 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20250108_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 25516567
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)